EM reports payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Merck Serono, Pierre Fabre, Bayer, Servier, Incyte, Eisai, and Roche; support for attending meetings or travel from AstraZeneca and Pierre Fabre; and participation on a data safety monitoring board or advisory board for MSD and Roche (all broadly related to treatments for metastatic colorectal cancer but unrelated to fruquintinib). FC reports payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Merck, Servier, and Pierre Fabre; support for attending meetings or travel from Merck; and participation on a data safety monitoring board or advisory board for Merck, Pfizer, MSD, Eisai, Pierre Fabre, Servier, Amgen, and Roche (all broadly related to treatments for metastatic colorectal cancer but unrelated to fruquintinib).